PROM1 and neoplasm: Lv et al. employed a sequential therapeutic strategy involving A54 peptide-modified SLNs carrying Oxaliplatin (OXA) targeting extratumoral cells, and A15 aptamer-modified SLNs loaded with salinomycin (SAL) aiming at CD133+ tumor stem cells [43].